I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

SABCS 2025

-
Coming soon
05:45 PM
Duration 15mins Hall 1
Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial
Aditya Bardia, Peter Schmid, Charles Geyer, Sara Hurvitz, Mo Rimawi, Nadia Harbeck, Miguel Martin, Sherene Loi, Gustavo Werutsky, Saji Shigehira, Kyung Hae Jung, Ogiya Akiko, Mauel Ruiz Borrego, Ahmet Alacacioglu, Pablo Perez Moreno, Tanja Badovinac Crnjevic, Chenglin Ye, Mona Shah, Mario Liste Hermoso, Nimali Withana, Jiong Wu
06:30 PM
Duration 2hrs San Antonio, USA
Comparative analysis of blood- and tissue-based PIK3CA mutation detection methods in the pivotal Phase 3 INAVO120 trial of palbociclib + fulvestrant ± inavolisib▼ in hormone receptor-positive, HER2-negative advanced breast cancer
Stephanie Hilz, Kevin Kalinsky, Dejan Juric, Nicholas Turner, Komal L. Jhaveri, Seock-Ah Im, Sibylle Loibl, Sherene Loi, Cristina Saura, Peter Schmid, Elin Shaddox, Norberto Pantoja Galicia, Cui Guo, Kate Li, Walter C. Darbonne, Rupal Desai, Pisutthida Karavagul, Junko Aimi, Stephanie Royer-Joo, Jennifer L. Schutzman, Thomas J. Stout, Chunyan Song, Philippe L. Bedard, Katherine E. Hutchinson
Duration 90mins San Antonio, USA
Relationship of early ctDNA dynamics with response to inavolisib▼ alone or in combination with endocrine therapy +/- CDK4/6 inhibitor in PIK3CA-mutated HR+, HER2- metastatic breast cancer from the first-in-human PhI/Ib trial
S. Hilz, M. K. Accordino, P. L. Bedard, A. Cervantes, V. Gambardella, E. P. Hamilton, A. Italiano, K. L. Jhaveri, D. Juric, K. Kalinsky, I. E.Krop, M. Oliveira, C. Saura, P. Schmid, N. C. Turner, E. S. Sokol, M. Childress, R. S. Huang, Z. J. Assaf, J. Aimi, S. Royer-Joo, J. L.Schutzman, K. E. Hutchinson
01:00 PM
Duration 90mins San Antonio, USA
Molecular features of response to palbociclib + fulvestrant ± inavolisib▼ in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial
Stephanie Hilz, Nicholas Turner, Kevin Kalinsky, Sibylle Loibl, Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Peter Schmid, Sherene Loi, Thomas J. Stout, Chunyan Song, Katherine E. Hutchinson, Dejan Juric
02:06 PM
Duration 3mins San Antonio, USA
Molecular features of response to palbociclib + fulvestrant ± inavolisib▼ in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial
Stephanie Hilz, Nicholas Turner, Kevin Kalinsky, Sibylle Loibl, Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Peter Schmid, Sherene Loi, Thomas J. Stout, Chunyan Song, Katherine E. Hutchinson, Dejan Juric
01:00 PM
Duration 90mins San Antonio, USA
Preliminary safety in the inavolisib▼ + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer
Einav Nili Gal-Yam, Yeon Hee Park, Amir Sonnenblick, Shani Breuer, Rinat Yerushalmi, Sherene Loi, Keun Seok Lee, Hilary Martin, Janelle Soong, Aleeza Sheikh, Kristin L. Griffiths, Richard Schwab, Eleftheria Michalopoulou, Timothy B. Fisher, Joo Hyuk So
02:03 PM
Duration 3mins San Antonio, USA
Preliminary safety in the inavolisib▼ + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer
Einav Nili Gal-Yam, Yeon Hee Park, Amir Sonnenblick, Shani Breuer, Rinat Yerushalmi, Sherene Loi, Keun Seok Lee, Hilary Martin, Janelle Soong, Aleeza Sheikh, Kristin L. Griffiths, Richard Schwab, Eleftheria Michalopoulou, Timothy B. Fisher, Joo Hyuk So
05:00 PM
Duration 15mins Hall 1
Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor
Hope S. Rugo, Sara M. Tolaney, Komal L. Jhaveri, Miguel Martin, Gregory A. Vidal, Luca Moscetti, Adam Brufsky, William J. Gradishar, Andreas Schneeweiss, Naoki Niikura, Anne Favret, Margarita Alfie, Keun Seok Lee, Sarah Khan, Merilin B. Feldman, Bann-mo Day, Lisa H. Lam, Walter C. Darbonne, Tharu M. Fernando, Pablo Perez-Moreno, Erica L. Mayer
06:30 PM
Duration 90mins San Antonio, USA
INAVO123: Phase 3 study of first-line inavolisib▼ / placebo + a cyclin-dependent kinase 4/6 inhibitor + letrozole in participants with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-sensitive advanced breast cancer
Reva K. Basho, Komal L. Jhaveri, Judy King, Sherko Kümmel, Yeon Hee Park, Venkatesh Krishnan, Patience Gyamfi, Xiaoyan Liu, Victor K. Khor, Aruna Mani, Javier Cortés